Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $13.01, while State Street SPDR S&P Biotech ETF trades at $159.27. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVDY | XBI | |
|---|---|---|
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $17.96 | $164.28 |
52-Week Low | $11.58 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $13.055, up 2.55% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividend income, with recent payouts ranging from $0.09 to $0.15 per share. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights the fund's strategy of selling NVIDIA call options to fund distributions, attracting income-focused investors.
The outlook for NVDY hinges on NVIDIA's volatility, which drives option premiums and dividends. However, investors sacrifice significant upside potential in NVIDIA's stock gains. Risks include underperformance versus direct NVIDIA ownership and fee drag. The ETF suits income seekers but may disappoint those seeking capital appreciation.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
